Neeraj Sharma, managing director and CEO of OneSource Specialty Pharma, told the Business Standard last month that demand for GLP-1 drugs such as semaglutide is exposing capacity gaps for Indias contract development and manufacturing organizations (CDMOs) across peptide APIs, sterile fill-finish facilities, injector devices, and glass cartridges
You are designing for someone who can only eat one serving
Some researchers have asked whether combining cagrilintide (the amylin component of CagriSema) with tirzepatide (the GIP/GLP-1 dual agonist) could produce even greater results
Epub 2020 Apr 15
Nicotine Dependence: Just as in other substances, preclinical data is showing GLP-1RAs can reduce nicotine-seeking behaviors
The specific, intense desire for certain foods, particularly carbohydrate-heavy and sugar-heavy options, diminishes